40 related articles for article (PubMed ID: 29198867)
1. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
[TBL] [Abstract][Full Text] [Related]
2. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
[TBL] [Abstract][Full Text] [Related]
3. Advances in covalent drug discovery.
Boike L; Henning NJ; Nomura DK
Nat Rev Drug Discov; 2022 Dec; 21(12):881-898. PubMed ID: 36008483
[TBL] [Abstract][Full Text] [Related]
4. 7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.
Irie T; Sawa M
Chem Pharm Bull (Tokyo); 2018; 66(1):29-36. PubMed ID: 29311509
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Kawahata W; Asami T; Kiyoi T; Irie T; Taniguchi H; Asamitsu Y; Inoue T; Miyake T; Sawa M
J Med Chem; 2018 Oct; 61(19):8917-8933. PubMed ID: 30216722
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNAEncoded Chemical Library.
Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
Chembiochem; 2017 Dec; 18(24):2441. PubMed ID: 29239533
[No Abstract] [Full Text] [Related]
7. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
[TBL] [Abstract][Full Text] [Related]
8. The Development of BTK Inhibitors: A Five-Year Update.
Tasso B; Spallarossa A; Russo E; Brullo C
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.
Zhang D; Gong H; Meng F
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443496
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
11. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
12. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
Xing L; Huang A
Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
Kawahata W; Asami T; Irie T; Sawa M
Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
[TBL] [Abstract][Full Text] [Related]
14. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]